| Stereochemistry | ACHIRAL |
| Molecular Formula | C18H19N3O2 |
| Molecular Weight | 309.3624 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C(C=C1)N2N=C3C(=CNC4=C3CCCCC4)C2=O
InChI
InChIKey=XRUUVUYJUULCBQ-UHFFFAOYSA-N
InChI=1S/C18H19N3O2/c1-23-13-9-7-12(8-10-13)21-18(22)15-11-19-16-6-4-2-3-5-14(16)17(15)20-21/h7-11,19H,2-6H2,1H3
| Molecular Formula | C18H19N3O2 |
| Molecular Weight | 309.3624 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
CGS-20625 is a potent and selective ligand for the central benzodiazepine receptor. It acts as a partial agonist of GABAA channel in vitro and produces anxiolytic and anticonvulsant effects in vivo. The drug has low bioavailability so its clinical applications are limited, and it is mainly used as a tool compound.
CNS Activity
Originator
Approval Year
PubMed
Patents
Sample Use Guides
In clinical studies of CGS-20625 pharmacokinetics, the drug was administered orally as a powder (20 mg), as PEG 400 solution or in gelatin capsules.
Route of Administration:
Oral
